RELEVANCE Trademark

Trademark Overview

On Friday, May 27, 2011, a trademark application was filed for RELEVANCE with the United States Patent and Trademark Office. The USPTO has given the RELEVANCE trademark a serial number of 85332656. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, April 7, 2023. This trademark is owned by Celgene Corporation. The RELEVANCE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Medical and scientific research, namely, conducting clinical trials for testing the safety and effectiveness of rituximab and lenalidomide
relevance

General Information

Serial Number85332656
Word MarkRELEVANCE
Filing DateFriday, May 27, 2011
Status710 - CANCELLED - SECTION 8
Status DateFriday, April 7, 2023
Registration Number4214952
Registration DateTuesday, September 25, 2012
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 15, 2012

Trademark Statements

Goods and ServicesMedical and scientific research, namely, conducting clinical trials for testing the safety and effectiveness of rituximab and lenalidomide

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, April 7, 2023
Primary Code042
First Use Anywhere DateFriday, November 18, 2011
First Use In Commerce DateFriday, November 18, 2011

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, April 7, 2023CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Saturday, September 25, 2021COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Thursday, October 19, 2017NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Thursday, October 19, 2017REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, October 17, 2017CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, September 25, 2017TEAS SECTION 8 & 15 RECEIVED
Monday, September 25, 2017COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Wednesday, July 29, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, September 25, 2012REGISTERED-PRINCIPAL REGISTER
Wednesday, August 22, 2012NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, August 21, 2012LAW OFFICE REGISTRATION REVIEW COMPLETED
Wednesday, August 15, 2012ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, August 9, 2012STATEMENT OF USE PROCESSING COMPLETE
Tuesday, July 17, 2012USE AMENDMENT FILED
Wednesday, August 8, 2012CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 17, 2012TEAS STATEMENT OF USE RECEIVED
Tuesday, July 10, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 15, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 15, 2012PUBLISHED FOR OPPOSITION
Wednesday, April 25, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, April 9, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, April 3, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, March 3, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, March 3, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 28, 2012ASSIGNED TO LIE
Friday, February 10, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 13, 2011NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 13, 2011NON-FINAL ACTION E-MAILED
Tuesday, September 13, 2011NON-FINAL ACTION WRITTEN
Tuesday, September 13, 2011ASSIGNED TO EXAMINER
Thursday, June 2, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 31, 2011NEW APPLICATION ENTERED

Related Keywords

relevance safety testing effectiveness rituximab lenalidomide trials clinical scientific research namely